Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $2.1 million.

  • Coherus Oncology's Non Operating Income rose 273.51% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 6531.55%. This contributed to the annual value of $3.4 million for FY2024, which is 3832.51% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Non Operating Income is $2.1 million, which was up 273.51% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Non Operating Income peaked at $2.9 million during Q2 2025, and registered a low of -$3.0 million during Q4 2024.
  • For the 5-year period, Coherus Oncology's Non Operating Income averaged around $926842.1, with its median value being $1.3 million (2022).
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 651666.67% in 2021, then skyrocketed by 530000.0% in 2023.
  • Coherus Oncology's Non Operating Income (Quarter) stood at -$385000.0 in 2021, then skyrocketed by 621.56% to $2.0 million in 2022, then crashed by 106.42% to -$129000.0 in 2023, then plummeted by 2262.02% to -$3.0 million in 2024, then soared by 170.27% to $2.1 million in 2025.
  • Its Non Operating Income stands at $2.1 million for Q3 2025, versus $2.9 million for Q2 2025 and $187000.0 for Q1 2025.